Related references
Note: Only part of the references are listed.Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
Christopher P. Venner et al.
BLOOD (2012)
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
Efstathios Kastritis et al.
BLOOD (2012)
Can Mortality Data Be Used to Estimate Amyotrophic Lateral Sclerosis Incidence?
Benoit Marin et al.
NEUROEPIDEMIOLOGY (2011)
Burden of Mortality Associated With Autoimmune Diseases Among Females in the United Kingdom
Sara L. Thomas et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2010)
Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen Aα-Chain Amyloidosis
Julian D. Gillmore et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Natural history and outcome in systemic AA amyloidosis
Helen J. Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Organ transplantation in hereditary apolipoprotein Al amyloidosis
J. D. Gillmore et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.
HJ Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Pathogenesis, diagnosis and treatment of systemic amyloidosis
MB Pepys
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2001)
Share Paper
